Method for prevention of cerebral vascular cramp in case of nontraumatic subarachnoidal hemorrhages due to aneurism rupture in brain vessels
SUBSTANCE: prior to aneurysm clipping, a lumbar drainage is installed, and after clipping, arachnoid dissection is performed and blood clots are removed. The following cisterns are opened: lateral cleft, ipsilateral carotid, chiasmatic, interpeduncular, contralateral carotid and terminal plate cisterns. Then, the terminal plate of the third ventricle is opened, cistern drainage is installed, lumbar drainage is opened, the liquor is withdrawn and the physiological solution is simultaneously introduced into the cistern drainage. Then the lumbar drainage is blocked and Forteplaze is injected into the cistern drainage. The surgical wound is sutured, the spinal fluid is sanitized. 6 hours after the intraoperative administration of Fortepaze, CT scannig of brain is performed and, in the absence of disturbances, Fortepaze is injected once again through the cistern drainage port.
EFFECT: reduction of postoperative complications.
5 cl, 4 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to using dermatan sulphate recovered from sulodexide for treating diseases involving metalloproteinase MMP-9: varicose veins and vascular malformations accompanied by a risk of thrombosis.
EFFECT: reducing and/or inhibiting individual's blood serum and saphena segments MMP-9 has been shown.
4 cl, 3 dwg, 13 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biotechnology, namely, to obtaining inhibitors of adhesion and/or aggregation of platelets, and can be used in medicine. A polypeptide, used as a component of a pharmaceutical composition and in sets for screening of the inhibitors of platelet adhesion or aggregation, is obtained in a recombinant way with the application of a matrix of the salivary gland cDNA of Anopheles stephensi.
EFFECT: invention makes it possible to obtain the polypeptide, possessing inhibiting activity with respect to platelet aggregation and/or inhibiting activity with respect to platelet adhesion.
10 cl, 4 dwg, 5 ex
SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.
EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.
4 dwg, 20 tbl, 6 ex
SUBSTANCE: before operation analysis of patient's haemostasis by means of thrombodynamics is carried out, and 12 hours before beginning operation anticoagulant prophylaxis with enoxaparin in dose 40 mg s/c 1 time per day performed. Analysis of thrombodynamics and coagulogram are repeated one day after operation, In case of detection of hypercoagulation (increase of one or some indices of thrombodynamics - initial speed of clot growth, stationary speed of clot growth, clot density, appearance of spontaneous clots) dose of enoxaparin is increased to 60 mg one time per day, and in case of detection of hypocoagulation (reduction of one or several indices of thrombodynamics - initial speed of clot growth, stationary speed of clot growth, clot density, delay of clot growth) dose of anticoagulant is reduced twice - 20 mg of enoxaparin per day.
EFFECT: method makes it possible to prevent development of post-operative venous thromboembolic complications in patients with colorectal cancer; said regimen of enoxaparin introduction provides prevention of both thromboembolic and hemorrhagic complications in said group of patients.
SUBSTANCE: thrombocyte aggregation-inhibiting heteromeric peptides based on imidazo[4,5-e]benzo[1,2-c;3,4-c']difuroxane are disclosed: , where R=Phe-Ile-Ala-Asp-Thr; Arg-Tyr-Gly-Asp-Arg; Lys-Ile-Ala-Asp-Asp; His-Ile-Gly-Asp-Asp.
EFFECT: improved properties.
1 dwg, 2 tbl, 4 ex
SUBSTANCE: invention relates to N-carb(arginyl)oxymethylimidazo[4,5-e]benzo[1,2-c; 3,4-c']difuroxane of formula .
EFFECT: improved properties of the compound.
1 dwg, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of pharmaceutics and represents a medication, possessing venomotor and anticoagulant action, which includes a dry extract of vine leaves, a base, preservatives, solvents, and is characterised by the fact that it additionally contains heparin in the form of a pharmaceutically acceptable salt, as the base it contains a hydrophilic gel-generating agent, as the solvents it contains purified water, propyleneglycol, ethyl alcohol rectified 95%, as the preservatives it contains nipagin, nipasol, with the following component ratio, wt %: dry extract of vine leaves with the content of the sum of flavonoides counter per rutin no less than 8% - 0.1-30.0; heparin in the form of a pharmaceutically acceptable salt - 100-1000 Units, hydrophilic gel-generating agent - 0.2-20.0; nipagin - 0.01-0.2; nipasol - 0.01-0.2, propyleneglycol - 3.0-70.0; ethyl alcohol rectified 95% - 3.0-70.0; purified water - the remaining part.
EFFECT: invention provides the creation of the medication in the form of a gel with good absorption, fast soaking, storage stability and acceptable organoleptic properties.
4 cl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a citrate of a compound described by formula (II) below, and a pharmaceutical composition containing said citrate.
EFFECT: experimental results of the present inventions prove that said citrate can inhibit activity of phosphodiesterase type 5 and can be used for treating erectile dysfunction, for inhibiting thrombocyte aggregation and treating thrombosis, for reducing pulmonary hypertension and treating cardiovascular diseases, asthma and diabetic gastroparesis.
SUBSTANCE: invention concerns preparing systemic and topical solid and soft dosage forms for external application in the form of a 1.5% hydrophilic gel and rectal capsules containing a 7.5% hydrophilic gel 1.9 g (in terms of the amount of the active substance of 0.14 g/capsule), for preventing and treating chronic venous insufficiency possessing anticoagulant, antithrombotic, anti-inflammatory, antiexudative and antitranssudative, capillary protective activities and improving haemorheology. An active pharmacologically active substance is presented by a substance of a potassium salt of sulphated arabinogalactan; a hydrophilic base is Aerosil, glycerol and pure water; the ingredients of the agent are taken in certain proportions, wt %.
EFFECT: invention provides the effective prevention and treatment of chronic venous insufficiency, has a broad spectrum of therapeutic action, improves haemorheology, tones the vessels and can be used in particular for treating varicose veins, thrombosis and posttraumatic oedema.
5 cl, 7 ex, 8 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a dosage form of Clopidogrel presented in the form of a solid gelatine capsule. The dosage form contains Clopidogrel hydrogen sulphate, lactose anhydride, microcrystalline cellulose, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate.
EFFECT: according to the invention, the dosage form of Clopidogrel contains a high amount of the active ingredient; it is prepared without the use of a wet granulation technique, and provides the more accurate dosage of the ingredients and the stability of the substances used.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biochemistry and biotechnology. Claimed hyaluronodase from Streptomyces koganeiensis ATCC 31394, including the N-terminal amino acid sequence AGENGATTTFDGPVA and having a molecular weight of 21.6 kDa, an isoelectric point (pI) in the range from 4.4 to 4.8 and enzymatic activity higher than 40000 IU/mg and lower than 50000 IU/mg. Described pharmaceutical or veterinary composition, containing the said hyaluronidase in a mixture with at least one suitable auxiliary substance and/or a carrier for treating diseases or states, for which decomposition of hyaluronic acid in tissues and organs is required or useful. The application of the said hyaluronidase as a reagent for the quantitative/qualitative determination of hyaluronic acid is claimed. The method of obtaining hyaluronic acid in accordance with the claimed invention includes the following stages: a) concentration by ultrafiltration through a filter with 10 kDA cut-off, dialysis of the supernatant, obtained after the fermentation of Streptomyces koganeiensis ATCC 31394, chromatography on a weak cation-exchanger by the elution of the column with a sodium-acetate buffer at pH 4.5 and separation of a protein fraction with hyaluronidase activity; b) diafiltration and chromatography of the protein fraction with hyaluronidase activity from stage a) on a strong anion-exchanger, separation of the protein fraction with hyaluronidase activity by the elution of the column with the buffer TRIS-HC1 and NaCl at pH 8 and separation of the protein fraction with hyaluronidase activity; c) chromatography of the protein fraction with hyaluronidase activity from stage b) on a strong cation-exchanger by the elution with a sodium phosphate buffer at pH 4.8 and separation of the protein fraction with hyaluronidase activity; d) chromatography of the protein fraction with hyaluronidase activity from stage C on a strong anion-exchanger after bringing pH to 5 and elution of the column with a sodium acetate buffer, with the further reduction of pH to 4 and elution of the column with the buffer solution of sodium acetate with obtaining in this way of two different protein fractions with different hyaluronidase activity, and selection of one of them, demonstrating higher hyaluronidase activity.
EFFECT: invention makes it possible to obtain the separated protein of hyaluronidase, demonstrating higher hyaluronidase activity.
11 cl, 9 dwg, 5 tbl, 3 ex
SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.
EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.
2 cl, 2 ex
SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for treating trophic ulcers and purulonecrotic involvements of lower extremities in diabetic patients. That requires a baseline therapy and a regional fibrinolytic therapy. Conducting the regional fibrinolytic therapy following applying a rubber bandage on the lower one-third of the shin is accompanied by administering Urokinase medac in a dose of 100 thousand units into the heel bone once a day within 5 days.
EFFECT: in the setting of reducing the total dosage of the preparation, the invention enables providing the high concentration of Urokinase medac in a pathological centre, improving microcirculation and metabolic processes in the involved tissues, accelerating the wound healing and reducing the length of hospital admission of the patients suffering from diabetic foot syndrome.
SUBSTANCE: invention refers to medicine, namely to surgery. A polyethylene tube is inserted into a mesentery. A solution containing proserine in a dose of up to 50 mg is introduced through the inserted tube. A synovial fluid 2 ml dissolved in normal saline 10 ml is additionally administered along the enteroenteroanastomosis.
EFFECT: method provides preventing peritoneal adhesions following the abdominal surgical operation by administering the preparations promoting better peristalsis and slide of the intestinal loop in the abdominal cavity.
SUBSTANCE: treating retinal and/or vitreous hemorrhages is ensured by a session of subcutaneous administration of Histochrom 0.5 ml into a mastoid bone, Echinacea compositum 1.0 ml into a temporal fossa, Gemase 2500-5000 IU parabulbary dissolved in Lymphomyosot 0.5-1.0 ml. The therapeutic course is 10-15 sessions, either daily or every second day.
EFFECT: faster resolution of the intraocular hemorrhages, prevention of retinal injuries by toxic decay products, higher visual acuity.
SUBSTANCE: invention relates to medicine, namely to therapy and pulmonology, and can be used for selection of tactics of treating thromboembolism of pulmonary artery. For this purpose computered tomography with bolus enhancement is performed to patient, areas of affection located more distally than thrombotic embolus are examined and number of respiratory movements per minute is taken into account. Presence of occluded vessel or vessels in examined areas is identified. Occlusion of segmental branch of pulmonary artery, located more distally than embolus, is assessed in one point irrespective of degree of vessel occlusion. Occlusion of each of lobar branches in case of affection of right middle lobar, left middle- and upper lobar branches of pulmonary artery is assessed in 2 points. Occlusion of upper lobar branch of pulmonary artery on the right, lower lobar branch of pulmonary artery on the left is assessed in 3 points. Occlusion of right lower lobar branch of pulmonary artery is assessed in 4 points. Occlusion of left main pulmonary artery is assessed in 7 points. Occlusion of right main pulmonary artery is assessed in 9 points. Occlusion of both main pulmonary arteries and/or pulmonary trunk is assessed in 17 points. After that, points are summed up. If the sum of points is from 1 to 6, anticoagulation therapy is performed with heparin. If the sum of points constitutes from 7 to 10 at rate of respiratory movements (RRM) lower than 18, another anticoagulation therapy is performed, at RRM more than 18 - thrombolytic therapy is performed. If the sum of points constitutes from 11 to 17, thrombolytic therapy is performed.
EFFECT: method provides possibility of operative objective assessment of degree of pulmonary bed affection and beginning of required therapy in due time.
5 dwg, 1 tbl, 4 ex
SUBSTANCE: invention refers to medicine, namely cardiology and concerns treating the patients with ST segment elevation acute myocardial infarction. That is ensured by the two-bolus intravenous administration of the thrombolytic preparation Fortelysine in a dose of 10 mg, and 30 minutes later in a dose of 5 mg.
EFFECT: presented mode of administration of Fortelysine provides the effective recovery of the antegrade coronary blood flow in the infarction-involved coronary artery in the patients with ST segment elevation acute myocardial infarction.
SUBSTANCE: treatment involves the paracervical introduction of a mixture containing klaforan 2 g, hemase 5000 units, 0.5% novocaine 20.0 ml, prednisolone 50.0 mg. The mixture is introduced once a day for 10 days.
EFFECT: effective treatment followed by recovery of hormonal and ovulatory ovarian function.
SUBSTANCE: invention relates to medicine, namely to ophthalmology, and deals with treatment of hemorrhages which occur, for instance, at the background of age-related macular degeneration with subretinal neovascularisation. For this purpose courses of treatment are carried out in sessions, each of courses includes carrying out mydriasis of affected eye, puncture of sclera to vitreous body and alternate introduction of medications. At the first session introduced is medication which inhibits factor of vessel growth (MIFVG), fibrinolytic medication (FM) and medication of expanding gas (MEG), for instance, sulfur hexafluoride. At the second session, in case of hemorrhage, the same medications are introduced. If there is no hemorrhage at the second and following sessions only MIFVG is introduced. Simultaneously with puncture of sclera paracentesis of cornea is performed through which drainage of moisture, normalising intraocular pressure, is carried out. MIFVG dose is calculated depending on degree of retina edema, FM and MEG doses are selected proportionally to hemorrhage value determined during fundus examination. Single MEG dose constitutes 0.05-0.35 ml. After sessions, at which MEG is introduced for 1-1.5 weeks control over resolution process is performed and it is recommended to patient to preserve "face down" head position until gas is resolved completely. 10-15 seconds after introduction of all included into particular treatment session medications, needle is removed, interval between sessions is selected equal from 3 weeks to 1.5 months.
EFFECT: method increases treatment quality due to elaboration of specific regimen of impact of said treatment methods, which ensures not only elimination of hemorrhage but also leads to elimination of it causes with minimisation of traumatic factors of treatment.
SUBSTANCE: invention refers to medicine, and can be used if extremity vein catheterisation is required for multiple intravenous introduction of drug solutions. That is ensured by vein catheterisation followed by change of an extremity position with respect to a patient's trunk so that an open pavilion of the catheter is arranged below a level of a patient's right atrium. An infrared imager is used to monitor an extremity surface condition within a projection of the catheter. If observing a region of local hyperthermia along the vein, its content is examined by ultrasound. A thrombus if any is sized up; tourniquets are applied below and above the region of local hyperthermia to complete sanguimotion cessation in the vein. Then, blood is taken from the vein to its devastation, and the volume of taken blood portion is measured that is followed by introduction of 2% lidocaine hydrochloride 0.5 ml and a thrombolytic solution at temperature +42°C in the volume necessary for complete vein filling. 3 minutes later, the whole liquid vein content is removed through the catheter, and the tourniquets are released, the vein content is examined by ultrasound. The presence of a thrombus requires another 3-minute tourniquet application with venous blood replacement by a local anaesthetic solution with a thrombolytic agent to stabilise thrombus size, then the catheter is removed, and the drugs are introduced by means of another catheter which is inserted in another extremity vein.
EFFECT: method allows higher safety and effectiveness of vein catheterisation due to early phlebitis detection and exact delivery of fibrinolytic agents to the thrombus to dissolve a "fresh" portion of the thrombus that allows reducing a risk of thromboembolism.
SUBSTANCE: pre-operative fasting venous blood 1 ml is sampled at room temperature 20-24°C into an anticoagulant-free vacuum system (test tube). The test tubes are delivered in a sealed container at temperature 2-8°C for 2 hours to a laboratory for immunoenzyme assay and analysed to determine anti-thyroid stimulating hormone receptor antibodies. If the antibody level is 1.5 units/l or more, a thyroidectomy is performed, whereas the antibody level of less than 1.5 units/l requires performing a subtotal thyroid resection according to standard techniques.
EFFECT: invention enables reducing a probability of recurrent thyrotoxicosis in the patients after subtotal thyroid resection.